Biotech Values

[DewDiligence]

IDIX Announces EASL Presentations for IDX184, IDX320

[The most intriguing of the four presentations, IMO, is the one in the fourth bullet below, which pertains to a combination of three direct antivirals, presumably IDX184 + IDX375 + IDX320. It’s only in-vitro data, but it could nevertheless give an early read as to whether a cocktail of drugs from the three main classes will provide additive or even synergistic activity.]

http://finance.yahoo.com/news/Idenix-Announces-Data-prnews-837772920.html?x=0&.v=1

›Idenix Announces Data Presentations at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)

Tuesday March 16, 2010, 9:44 am EDT

CAMBRIDGE, Mass., March 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts have been accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL, April 14-18, 2010 in Vienna, Austria). Full abstracts can now be viewed at the EASL website at www.easl.eu.

The accepted abstracts are as follows:

• Lalezari, et al, “Antiviral Activity, Pharmacokinetics and Safety of IDX184 in Combination with Pegylated Interferon (PegIFN) and Ribavirin (RBV) in Treatment-Naïve HCV Genotype 1-Infected Subjects”, will be presented in a poster session beginning on Thursday, April 15.

• Good, et al, “Preclinical Pharmacokinetic Profile of IDX320, a Novel and Potent HCV Protease Inhibitor”, will be presented in a poster session on Friday, April 16.

• Lallos, et al, “In Vitro Antiviral Activity of IDX320, a Novel and Potent Macrocyclic HCV Protease Inhibitor”, will be presented in a poster session on Friday, April 16.

• La Colla, et al, “A Triple Combination of Direct-Acting Antiviral Agents Demonstrates Robust Anti-HCV Activity In Vitro” will be presented in a poster session on Friday, April 16.‹